AZITRA INC (AZTR)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$0.18-0.28%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AZTR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -78.3% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
AZTR — earnings miss
Dated 2026-05-13
and shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Why it matters: Advancing clinical trials is key for AZITRA's growth. Delays could hurt future prospects.
Supportive ifThey announced they finished an important step in a clinical trial.
Worry ifThere are more delays or problems with clinical trial timelines.
Why it matters: Updates on cash flow will show how well Azitra handles losses and funding.
Worry ifCash and cash equivalents are up, showing good management and funding.
Less concerning ifCash levels are down again, raising worries about financial health.
Why it matters: Updates on cash flow will show how Azitra handles losses and funding.
Watch forCash flow improves a lot after the private placement.
Also watch forCash flow remains negative or worsens despite the private placement.
Why it matters: Managing cash flow well is key for keeping operations running. It also helps fund growth.
Worry ifA report will show smaller operating losses or better cash flow numbers.
Less concerning ifAn increase in operating losses or a decline in cash reserves.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$322 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $992 loss on $10,000 · 9.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,544 loss on $10,000 · 85.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Good results would show that Azitra's anti-wrinkle product works. This would help investors feel more confident.
Supportive ifA press release will confirm good results from the human study for the ATR-COSF program.
Worry ifA press release indicating the human study did not meet its primary endpoints.
Why it matters: Updates on ATR-12 enrollment will show if it can treat Netherton syndrome.
Watch forEnrollment is going well. There is strong interest and good chances.
Also watch forEnrollment is paused or slowed. This shows possible challenges.
Why it matters: Getting financing will give AZITRA the money it needs. This is important for its growth.
Supportive ifThey shared news about a successful PIPE financing deal.
Worry ifThere are no updates or failed efforts to get financing.
Why it matters: A continued decline in cash could signal financial stress and impact ongoing projects.
Worry ifCash and cash equivalents drop below $6 million.
Less concerning ifCash and cash equivalents stay stable or rise above $6.7 million.
Why it matters: Topline data could prove Azitra's method for treating Netherton syndrome. This may affect future funding.
Supportive ifThe Phase 1b trial data shows good safety and effectiveness.
Worry ifThe Phase 1b trial data shows safety concerns or lack of efficacy.
Why it matters: Earnings results will show if the company can recover from recent losses. A miss could signal deeper issues.
Worry ifEarnings report shows a smaller loss than the previous quarter.
Less concerning ifEarnings report shows a larger loss than the previous quarter.
Why it matters: Positive results would show ATR-COSF works well as a cosmetic ingredient.
Supportive ifThe ex vivo studies show good results. They have strong anti-wrinkle effects.
Worry ifResults from the ex vivo studies show no strong anti-wrinkle effects.
Why it matters: The meeting's results will affect how the company is run and its future plans. This will change how investors feel.
Watch forA successful vote on key proposals at the reconvened meeting on June 15, 2026.
Also watch forFailure to reach a quorum or pass key proposals at the reconvened meeting.
Why it matters: Good results would show Azitra's anti-wrinkle product works. This would help investors feel better.
Supportive ifThe human study shows clear wrinkle reduction. This matches what management said.
Worry ifThe human study does not show wrinkle reduction. This goes against what was claimed.
Why it matters: Starting this study will confirm progress in the ATR-COSF program, which targets a large cosmetic market.
Supportive ifThe study for ATR-COSF on humans will start as planned.
Worry ifThere is a delay in starting the human study for ATR-COSF.
Why it matters: A drop below this level may signal cash flow issues, affecting ongoing trials and operations.
Worry ifCash and cash equivalents are over $5 million. This shows good cash flow management.
Less concerning ifCash and cash equivalents fall below $5 million.
Why it matters: Topline data will show if ATR-04 can effectively treat EGFR inhibitor-associated rash. This is a big market need.
Supportive ifTopline data from the first cohort of the ATR-04 trial is reported as positive.
Worry ifThe data shows no major worries about how well it works or safety.
Why it matters: Completing enrollment helps share data quickly. It also helps meet the trial goals.
Supportive ifEnrollment in the ATR-04 trial is completed ahead of schedule.
Worry ifEnrollment in the ATR-04 trial is delayed beyond Q4 2026.